Citation Impact
Citing Papers
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2012 Standout
Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
2011
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
2009
Risk Factors for Venous Thromboembolism
2003 Standout
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours
2002
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
2017 Standout
Global patterns and trends in colorectal cancer incidence and mortality
2016 Standout
Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting
1996
Prediction of the response of colorectal cancer to systemic therapy
2002
A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
2003 Standout
10 Disease assessment and management of the vasculitides
1997
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
2009 Standout
Microsatellite Instability in Colorectal Cancer
2010 Standout
Air travel and thrombosis
2002
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
1997 StandoutNobel
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
Ovarian cancer
2014 Standout
Olaparib: First Global Approval
2015
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Cancer Statistics, 2006
2006 Standout
Effect of pegylation on pharmaceuticals
2003 Standout
Pancreatic cancer
2016 Standout
Incidence of Air Travel–Related Pulmonary Embolism at the Madrid-Barajas Airport
2003
Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography
1995
Severe Pulmonary Embolism Associated with Air Travel
2001
The Hallmarks of Cancer
2000 Standout
Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library
1996
Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data
2015
The neural cell adhesion molecule NCAM in multiple myeloma
1996
Diagnostic and therapeutic applications of monoclonal antibodies in colorectal cancer
1998
Expression of neural cell adhesion molecules (polysialylated form of neural cell adhesion molecule and L1‐cell adhesion molecule) on resected small cell lung cancer specimens: In relation to proliferation state
2001
Clinical predictors of bevacizumab-associated gastrointestinal perforation
2010
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer
1997
Colorectal cancer
2019 Standout
Antiangiogenic therapy—evolving view based on clinical trial results
2012
Polymer conjugates as anticancer nanomedicines
2006 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
2014
A molecular map of mesenchymal tumors
2005
Prevention of Venous Thromboembolism
2004 Standout
EMT: 2016
2016 Standout
Crystal structure of a chimeric Fab′ fragment of an antibody binding tumour cells
1992
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
2011
Protease-Activated Drug Development
2012
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Antiangiogenic therapy in oncology: current status and future directions
2016
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Characterization of In Vivo Immunoliposome Targeting to Pulmonary Endothelium
1990
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
In vivo imaging of tumors with protease-activated near-infrared fluorescent probes
1999 Standout
Travel as a Risk Factor for Venous Thromboembolic Disease
1999
Caelyx®
2001
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
A Conditional Mouse Model of Synovial Sarcoma: Insights into a Myogenic Origin
2007 StandoutNobel
Review: Biological relevance of disseminated tumor cells in cancer patients
2008
Ovarian Cancer Development and Metastasis
2010
Regulatory networks defining EMT during cancer initiation and progression
2013 Standout
The dawning era of polymer therapeutics
2003 Standout
Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition
2009
Folate status and the safety profile of antifolates
2002
Patterns of Colorectal Cancer Care in the United States: 1990–2010
2015
Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers
2005
Protein, peptide and non-peptide drug PEGylation for therapeutic application
2004
Polysialic Acid, a Glycan with Highly Restricted Expression, Is Found on Human and Murine Leukocytes and Modulates Immune Responses
2008 StandoutNobel
The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling
2005 Standout
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
2001
Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer
2002
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Immune Versus Natural Selection: Antibody Aldolases with Enzymic Rates But Broader Scope
1997 StandoutScienceNobel
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer
2001
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
2001 Standout
Accelerated Clearance of Polyethylene Glycol-Modified Proteins by Anti-Polyethylene Glycol IgM
1999
Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer
2002
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
2003 Standout
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
2001 Standout
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
2011 Standout
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Polysialic acid governs T-cell development by regulating progenitor access to the thymus
2009 StandoutNobel
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
2011
Works of JA Ledermann being referenced
Predicting biomarkers for ovarian cancer using gene-expression microarrays
2004
Detection of the neural cell adhesion molecule (NCAM) in serum of patients with small-cell lung cancer (SCLC) with “limited” or “extensive” disease, and bone-marrow infiltration
1994
Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control
2014
Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A
1988
Clinical trials in gynecological cancer
2007
Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies
1994
The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies
1994
Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma – implications for radioimmunotherapy
1992
Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer
1989
A phase‐i study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin a to suppress the immune response
1991
Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy
1999
Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.
1997
Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)
2014
Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.
2011
Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06
2000
Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial
2013
PHASE I/II STUDY OF CHIMERIC B72.3 ANTIBODY IN RADIOIMMUNOTHERAPY OF COLORECTAL-CARCINOMA
1990
Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer
1999
ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC)
2010
Acute pulmonary embolism following air travel
1983
Peripheral blood stem cell transplantation in common solid tumours: Passing phase or new era?
1996